IndustryCompany release

SpyGlass Pharma buys lens maker AVS and reports four-year glaucoma implant data

🇺🇸 SpyGlass Pharma, Inc. (SGP) · Thu 12 Nov 2026

The company acquired Advanced Vision Science from Santen to secure IOL supply for its Phase 3 glaucoma programme, and has begun implanting patients with its second candidate, BIM-DRS.

SpyGlass Pharma reported third-quarter 2026 results and corporate updates on 11 November. The company said that in October it bought Advanced Vision Science (AVS) from Santen for about $13 million.

The purchase is intended to secure manufacturing of intraocular lenses (IOLs) for the Bimatoprost Drug Pad-IOL System, which is in Phase 3 development for open-angle glaucoma and ocular hypertension.

SpyGlass also reported four-year first-in-human data for the programme. These showed a mean intraocular pressure (IOP) reduction of 37%, with no product-related adverse events to date.

The company also said the first patients have been implanted with its Bimatoprost-Drug Ring System (BIM-DRS) in a first-in-human study. It reported cash of $215.8 million, which it expects to fund operations through 2028.

What it means for your team

  • Bringing IOL manufacturing in-house addresses a supply-chain dependency for a drug-device combination product heading through Phase 3, and CMC and quality teams will watch how the transfer is managed.
  • Four-year safety follow-up with no product-related adverse events to date is relevant to long-term safety expectations for sustained-release ocular implants, though the data come from a first-in-human study.
  • The start of BIM-DRS implantation adds a second delivery approach to the company's bimatoprost portfolio.
  • The stated cash runway through 2028 suggests the Phase 3 programme is funded for the medium term.

Company's press release (SEC filing): SpyGlass Pharma, Inc. ↗

Article written by VigiEye from the official source (SpyGlass Pharma, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →